There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ardelyx (ARDX – Research Report) and Eli Lilly & Co (LLY – Research Report) with bullish sentiments.
Ardelyx (ARDX)
According to TipRanks.com, Nochomovitz is a 5-star analyst with an average return of
Currently, the analyst consensus on Ardelyx is a Strong Buy with an average price target of $11.08.
See today’s best-performing stocks on TipRanks >>
Eli Lilly & Co (LLY)
Bank of America Securities analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co yesterday and set a price target of $700.00. The company’s shares closed last Tuesday at $625.48, close to its 52-week high of $636.41.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of
Currently, the analyst consensus on Eli Lilly & Co is a Strong Buy with an average price target of $661.81, implying a 5.0% upside from current levels. In a report issued on January 5, Leerink Partners also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ARDX:
- Ardelyx provides update, 2024 strategic priorities
- Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
- Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
- Ardelyx call volume above normal and directionally bullish
- Ardelyx reports employee inducement grants
